Pacific Biosciences
PACB
PACB
272 hedge funds and large institutions have $2.86B invested in Pacific Biosciences in 2023 Q4 according to their latest regulatory filings, with 49 funds opening new positions, 103 increasing their positions, 75 reducing their positions, and 45 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
4.8% more ownership
Funds ownership: 104.4% → 109.2% (+4.8%)
9% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 45
0% more funds holding
Funds holding: 272 → 272 (0)
Holders
272
Holding in Top 10
6
Calls
$54M
Puts
$22M
Top Buyers
| 1 | +$196M | |
| 2 | +$45.9M | |
| 3 | +$34.5M | |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$28.5M |
| 5 |
JSP
Jackson Square Partners
Larkspur,
California
|
+$27.2M |
Top Sellers
| 1 | -$39.6M | |
| 2 | -$25.5M | |
| 3 | -$12M | |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$11.7M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$9.42M |